Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Phase 1

Terminated

Brief Summary: This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.

Detailed Description: This is an open label study, intended as a safety and efficacy assessment prior to a full comparator study. In this Phase I study, cells administered will be delivered in 6-10 intramyocardial injections that will be tested in 20 patients and 10 patients will be controls with a total of 30 HLHS patients.

A total of 30 patients with HLHS will be enrolled in a staged enrollment process. In this open-labeled study, a maximum of 20 patients will eventually receive intramyocardial injection of the allogeneic mesenchymal stem cells and 10 control patients with no cell injection. The enrollment of the patients will occur in two stages groups: Group A and Group B. In Group A, 10 consecutive HLHS patients will be initially enrolled in the allogenic MSCs treatment arm to determine feasibility and safety. After 6 months of the last enrolled patient in Group A, all Group A patients will be assessed in order to determine whether it is feasible and safe, including the harvesting, processing, and administering of the allogeneic MSCs. Thereafter, Group B will start enrolling a total of 20 HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio, respectively, in order to have 10 allogeneic MSCs-treated patient and 10 control patients. At the completion of this Phase I clinical study, the total enrolled cohort will be 20 patients treated with allogeneic MSCs and 10 patients in the control arm.

Recruitment & Eligibility

Inclusion Criteria

Subjects with hypoplastic left heart syndrome (all types) requiring BDCPA surgery.

Exclusion Criteria

Have HLHS and restrictive or intact atrial septum.
Be undergoing the Norwood procedure that do not have HLHS.
Have significant coronary artery sinusoids.
Require mechanical circulatory support prior to surgery.
Have an underlying evidence of arrhythmia requiring anti-arrhythmia therapy.
Parent or guardian unwilling or unable to comply with necessary follow-up(s)
Be serum positive for HIV, hepatitis BsAg (B Surface Antigen) or viremic hepatitis C.
Be unsuitable for inclusion in the study, in the opinion of the investigator.
Need for concomitant surgery for aortic coarctation or tricuspid valve repair.

Arm && Interventions

Group	Intervention	Description
Group A - Allo-hMSCs	Allo-hMSCs	Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10\^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
Group B	Placebo	Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.

Primary Outcome Measures

Name	Time	Method
Monitor major adverse cardiac events	1 month after injection	Monitoring of events includes death, sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.

Secondary Outcome Measures

Name	Time	Method
Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation	baseline, 24 weeks and 1 year	as measured by serial echocardiograms and MRI scans.
Assessment of Co-morbidity	up to 12 months follow-up	Assessment of cardiovascular mortality, all-cause morbidity, Cardiovascular morbidity, re-hospitalizations, need for transplantation.
Number of participants with incidence of mortality or need for transplantation after the BDCPA operation	One year after injections	Assessed through the number of participants with adverse events, hospitalizations, or transplantations.
Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation	12 months post operative	Changes in weight, height, and head circumference will be measured

Locations (2): University of Maryland Medical Center
🇺🇸
Baltimore, Maryland, United States
Johns Hopkins Hospital
🇺🇸
Baltimore, Maryland, United States